Only your physician can determine if the AVISE SLE Monitor test is right for you.

While there is no cure for lupus, routine monitoring with AVISE^® SLE Monitor can offer insights to help you and your doctor manage your symptoms, track lupus flares, gauge if your treatment plan is working, and protect your organs from irreversible damage^2,5.

• Your reported symptoms
• Physician observations
• Abnormal biomarkers – Tracking your biomarker levels over time can help reveal important changes in your disease activity and possible organ involvement, which can be helpful in managing your condition.

If you’re ready to start proactively managing your lupus, ask your provider about the AVISE SLE Monitor test.  Download this letter to help start the conversation with your health care provider.

Getting an AVISE test is easy

Step 1: Fill out this form and send your provider information about AVISE testing.

Step 2: Speak with your healthcare provider to determine if AVISE Monitor is right for you.

Step 3: Test results will be sent to your physician within 5 business days.

AVISE SLE Monitor provides additional information to help you and your doctor assess:

• Your lupus disease activity
• If you may be at risk for possible kidney damage (lupus nephritis) - It is estimated that 40% of lupus patient will develop some degree of kidney damage, so monitoring for possible organ involvement becomes critical when preventing this type of tissue damage.
• Improvements in your condition due to therapy

This added insight might be the clue needed to help your doctor achieve and maintain control over your lupus.

What is included in the SLE Monitor test?

The AVISE SLE Monitor test includes:

• A unique lupus biomarker called EC4d, clinically proven to track disease activity better than traditional lupus tests alone.
  • EC4d is a patented lupus biomarker that measures complement activation, a key part of the lupus disease process. EC4d acts like a “fingerprint” left behind by the lupus disease process.
• A state-of-art testing method to help better assess changes in anti-dsDNA levels. These changes provide additional insights that can guide clinical decisions.
• PC4d is a patented lupus biomarker significantly associated with history of thrombosis.
• The Anti-C1q biomarker, a unique biomarker test clinically proven to help assess lupus activity and possible kidney damage.

In addition: The test also incorporates C3 & C4 testing. When low levels of these proteins are detected in the blood, this could indicate higher lupus disease activity.

References

1. Merrill J, et al. Lupus Science Medicine. 2018.
2. Buyon J, et al. Lupus Science & Medicine. 2016.
3. Data on file. Anti-dsDNA significantly correlates to clinical SELENA - SLEDAI. Exagen,Inc. 2017.
4. Lupus Foundation of America. resources.lupus.org/collections/diagnos­ing-lupus. 2017.

Additional Patient Information